Container
Latest Glaxo Group Limited Patents:
- Method of producing a recombinant protein
- Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
- Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
- Compounds
- Modified proteins and peptides
Description
The broken lines in the drawings illustrate the portions of the design that form no part of the claim.
Claims
The ornamental design for a container, as shown and described.
Referenced Cited
U.S. Patent Documents
Foreign Patent Documents
D128365 | July 1941 | Daum |
D183127 | July 1958 | Johnson |
D185031 | April 1959 | Menefee, Jr. |
D187559 | March 1960 | Horne |
D219262 | November 1970 | Lamelet |
D392894 | March 31, 1998 | Steih et al. |
D419058 | January 18, 2000 | Roth et al. |
D427057 | June 27, 2000 | Roth et al. |
D427514 | July 4, 2000 | Roth et al. |
D427515 | July 4, 2000 | Roth et al. |
D428813 | August 1, 2000 | Haley |
D441297 | May 1, 2001 | Albright et al. |
D455351 | April 9, 2002 | Bailey |
D467179 | December 17, 2002 | Nelson et al. |
D469699 | February 4, 2003 | Crawford et al. |
D479999 | September 30, 2003 | Moore |
D497549 | October 26, 2004 | Andrews et al. |
D500447 | January 4, 2005 | Snyder |
D505864 | June 7, 2005 | Snyder |
D513591 | January 17, 2006 | Ducret |
D531903 | November 14, 2006 | Haubein |
D538661 | March 20, 2007 | Wolf et al. |
D548087 | August 7, 2007 | Wolf et al. |
D577593 | September 30, 2008 | Hestehave |
D585293 | January 27, 2009 | Honkawa |
D595135 | June 30, 2009 | Goetz |
D608210 | January 19, 2010 | Kuzma et al. |
D609570 | February 9, 2010 | Suchenski et al. |
D610010 | February 16, 2010 | Schwartz et al. |
D614030 | April 20, 2010 | Kuzma et al. |
D615403 | May 11, 2010 | Goetz |
D615870 | May 18, 2010 | Bourne |
D620361 | July 27, 2010 | Scott |
D620362 | July 27, 2010 | Boukobza |
D620758 | August 3, 2010 | Smiedt et al. |
D621660 | August 17, 2010 | Smiedt et al. |
D621715 | August 17, 2010 | Schwartz et al. |
D623012 | September 7, 2010 | White et al. |
D623529 | September 14, 2010 | Yourist et al. |
D624427 | September 28, 2010 | Yourist et al. |
D631285 | January 25, 2011 | Smiedt et al. |
D631286 | January 25, 2011 | Smiedt et al. |
D632576 | February 15, 2011 | Hermel |
D644929 | September 13, 2011 | White et al. |
D648633 | November 15, 2011 | Boukobza |
D650675 | December 20, 2011 | Schwartz et al. |
D650676 | December 20, 2011 | Schwartz et al. |
D650689 | December 20, 2011 | Schwartz et al. |
D652307 | January 17, 2012 | White et al. |
D653951 | February 14, 2012 | Scott |
D661993 | June 19, 2012 | Denham et al. |
D668157 | October 2, 2012 | Colloud |
D699108 | February 11, 2014 | Cox et al. |
D699110 | February 11, 2014 | Cox et al. |
2087392 | April 1999 | GB |
2088297 | November 1999 | GB |
3025172 | June 2006 | GB |
Patent History
Patent number: D721586
Type: Grant
Filed: Nov 7, 2013
Date of Patent: Jan 27, 2015
Assignee: Glaxo Group Limited (Brentford, Middlesex)
Inventors: Tim Sharpe (Warwick), Jonathan Stewart (Warwick), Stuart Cole (Warwick)
Primary Examiner: Ian Simmons
Assistant Examiner: Dana L Meyrow
Application Number: 29/471,974
Type: Grant
Filed: Nov 7, 2013
Date of Patent: Jan 27, 2015
Assignee: Glaxo Group Limited (Brentford, Middlesex)
Inventors: Tim Sharpe (Warwick), Jonathan Stewart (Warwick), Stuart Cole (Warwick)
Primary Examiner: Ian Simmons
Assistant Examiner: Dana L Meyrow
Application Number: 29/471,974
Classifications
Current U.S. Class:
D9/500;
D9/539